-
Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact
•
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with Beijing Mabworks Biotech Co., Ltd to collaborate in biomedical technology services and new drug development. The partnership will cover drug discovery, process R&D, production, quality control, and clinical research through joint development, commissioned R&D, technical…
-
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
•
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a unit of US major Johnson & Johnson, to collaborate on the development of antibody drug conjugates (ADCs). The partnership will leverage DAC Bio’s proprietary ADC platform and Janssen’s antibody expertise for up to five targets.…
-
NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms
•
The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA) jointly released a notification outlining 2022 work goals for urban employee and rural/residential Basic Medical Insurance (BMI) schemes, focusing on improving funding standards and expanding accessibility. Funding Standards Household Registration RelaxationThe government will loosen restrictions…
-
Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy
•
China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth Biological Technology Co., Ltd’s NR082 for the treatment of Leber hereditary optic neuropathy (LHON) caused by the G11778A mutation. The drug, an innovative intraocular injection gene therapy, uses a recombinant adeno-associated virus serotype 2 vector…
-
Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors
•
China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb) targeting T cell immunoglobulin and ITIM domains (TIGIT) and poliovirus receptor related immunoglobulin domain (PVRIG), has been accepted by the Center for Drug Evaluation (CDE). The drug, co-developed with US firm Adimab, is aimed at…
-
Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M
•
Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its initial public offering (IPO) on the Hong Kong Stock Exchange. The company’s shares (02297) were priced at HKD 6.24 each, giving it an initial market valuation of over HKD 6 billion (USD 764 million). Company…
-
MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC
•
The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US firm MicuRx Pharmaceuticals Inc. on Shanghai’s Sci-Tech Innovation Board (STAR). The company, established in 2007, focuses on developing novel drugs for infectious diseases and kidney disorders. Company BackgroundMicuRx has a pipeline of in-house developed drugs…
-
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
•
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in China for Pemazyre (pemigatinib), the world’s first targeted therapy for cholangiocarcinoma (bile duct cancer). The drug, an FGFR2-targeted protein kinase inhibitor, was originally discovered by US biotech Incyte Therapeutics and licensed to Innovent for Greater…
